Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386359 · ClinicalTrials.gov registry record
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 914
- Enrollment target
NCT01386359 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 914 participants.
The verdict
NCT01386359 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 914 participants
- Enrollment target
Study Summary
To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment, occur in patients taking Nulojix (belatacept) in a real-world setting.
Interventions
- DRUG No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 914 participants |
| Start Date | 2012-02-29 |
| Est. Completion | 2019-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01386359
The ClinicalTrials.gov registry entry for NCT01386359 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 914 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT01386359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01386359 about?
NCT01386359 is a clinical study titled "Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant". To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment, occur in patients taking Nuloji...
What is the current status of trial NCT01386359?
This trial is currently completed. The enrollment target is 914 participants. The study started on 2012-02-29. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT01386359?
The interventions under investigation include: No Intervention (DRUG).
Who is sponsoring clinical trial NCT01386359?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.